Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
infection is a rare but highly lethal infectious disease. Clinically, is the strain most commonly isolated from patients with infections. is an opportunistic pathogen that can cause local or invasive infections in immunocompromised patients. In this article, a case of breakthrough infection in an immune thrombocytopenia (ITP) patient during caspofungin and isavuconazole combined therapy is reported. Metagenomic next-generation sequencing (mNGS) played a crucial role in the diagnosis of the breakthrough infection in this patient. Upon receiving combined therapy with intravenous voriconazole and nebulized amphotericin B, the patient demonstrated significant clinical improvement and was subsequently discharged.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336242 | PMC |
| http://dx.doi.org/10.3389/fcimb.2025.1625007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breakthrough SARS-CoV-2 outcomes in immune-disordered people during the Omicron era: a prospective cohort study.
BMJ Public Health
August 2025
Epidemiology and Data Management Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases Division of Intramural Research, Bethesda, Maryland, USA.
Introduction: Immune-deficient/disordered people (IDP) elicit a less robust immune response to COVID-19 vaccination than the general US population. Despite millions of IDP at presumed elevated risk, few population-level studies of IDP have been conducted in the Omicron era to evaluate breakthrough infection-related outcomes.
Methods: We followed a prospective cohort of 219 IDP and 63 healthy volunteers (HV) in the USA from April 2021 (Alpha variant peak) to July 2023 (Omicron XBB variant peak).
Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma.
Oncol Res
September 2025
Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Cholangiocarcinoma (CCA) is a fatal bile duct malignancy. CCA is intrinsically resistant to standard chemotherapy, responds poorly to it, and has a poor prognosis. Effective treatments for cholangiocarcinoma remain elusive, and a breakthrough in CCA treatment is still awaited.
View Article and Find Full Text PDFSafety, immunogenicity and efficacy of the Shingrix vaccine in immunocompromised varicella zoster virus naïve pediatric patients.
Vaccine
September 2025
Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital/ University Medical Center Utrecht, Utrecht, the Netherlands; Faculty of Medicine, Utrecht University, Utrecht, the Netherlands.
Background: Pediatric patients with autoimmune and inflammatory diseases often require immunosuppressive therapy, which increases their susceptibility to infections, including varicella-zoster virus (VZV). While the live attenuated varicella vaccine is contraindicated in most immunocompromised children, the recombinant subunit vaccine, Shingrix, may offer an alternative preventive strategy. However, data on its safety, immunogenicity, and efficacy in pediatric VZV-naïve patients remain limited.
View Article and Find Full Text PDFA key goal of vaccinology is to train the immune system to combat current pathogens while simultaneously preparing it for future evolved variants. Understanding factors contributing to anticipatory breadth, wherein affinity maturation against an ancestral strain yields neutralization capacity against evolved variants, is therefore of great importance. Here, we investigated the mechanism of anticipatory breadth development in a public antibody family targeting the functionally restricted ACE2 binding site on SARS-CoV-2.
View Article and Find Full Text PDF[Treatment of adult T-cell leukemia/lymphoma: past, present, and future].
Rinsho Ketsueki
September 2025
Department of Hematology and Rheumatology, Kagoshima University.
Adult T-cell leukemia/lymphoma (ATL) is a T-cell malignancy caused by human T-cell leukemia virus type I (HTLV-1). Treatment strategies have been established by classification of ATL as aggressive (acute, lymphoma, and chronic ATL with any unfavorable prognostic factors) or indolent (smoldering and chronic ATL without any unfavorable prognostic factors). The standard of care (SOC) for aggressive ATL has been dose-intensified multi-agent chemotherapy.
View Article and Find Full Text PDF